| Biomedical industry in China more competitive in | | | | the world Pharmaceutical companies Industry |
| the path?? Biomedical industry as an example of | | | | have been directly or indirectly enter the Chinese |
| Shanghai | | | | market, they not only approved drugs |
| I. Development of China's biomedical industry and | | | | themselves quickly registered in China, while |
| means of | | | | production line built in China production, and some |
| Biotechnology in China based on 70 years | | | | clinical trials of new drug development will be |
| follow-up study carried out into the 90's, started | | | | moved to China to complete. The impact of |
| in the field of medicine and agriculture | | | | foreign drug development. 1997 U.S. biotechnology |
| industrialization process. Compared with developed | | | | venture capital has more than 50 billion U.S. dollars, |
| countries, China's market is small, but the growth | | | | and the additional annual investment of 50 billion |
| rate significantly higher than the global market | | | | U.S. dollars, while China's 10 years on the total |
| growth. Domestic bio- Pharmaceutical market Not | | | | input biopharmaceutical less than 40 billion yuan. |
| yet formed a monopoly competition, industry | | | | Intellectual property disputes. IP protection greatly |
| concentration is low, the majority of enterprises | | | | limit the domestic manufacturers of imitation |
| are small-scale development phase. In general, | | | | behavior, and our very few drugs with |
| showed the following characteristics: First, there | | | | independent property rights. |
| are considerable reserves of talent and | | | | Overall, China's biomedical industry shows a small |
| technology. Currently engaged in biotechnology | | | | scale, started late feature, with Europe and the |
| research and development staff for almost 2 | | | | United States, Japan and other advanced |
| million people, more and more students to study | | | | countries is also at a disadvantage. From the |
| abroad have returned, bringing advanced | | | | perspective of industry life cycle, biological |
| technology. Take 1% of the work of the Human | | | | pharmaceutical industry in the industrial growth |
| Genome Project and the Chinese genome project | | | | phase, and will have strong market prospects, is |
| start-up, for the establishment of gene banks for | | | | contested national industry competition. From a |
| the Chinese nation and laid a good foundation for | | | | global point of view, after years of development |
| the research of genetically modified plants and | | | | and market competition, coupled with the |
| animals has yielded some results. Second, China | | | | government lost no time to boot, many |
| has unique biological resources. Uneven economic | | | | developed countries in technology, personnel, |
| development, making China both the developed | | | | capital-intensive areas, has gradually formed a |
| and developing various diseases, with | | | | bio-gathering area, thus forming a more perfect |
| disease-related genes provides a unique resource; | | | | bio-pharmaceutical industry chain and industry |
| has good diversity; China's animal and plant | | | | cluster. The United States has formed a San |
| resources are very rich. Third, many factors | | | | Francisco, Boston, Washington, North Carolina, five |
| contribute to the development of the industry. | | | | San Diego area biotechnology industry. Silicon |
| Support of national policy, Pharmaceutical Industry | | | | Valley biotech industry which accounts for the U.S. |
| Attention to the introduction of venture capital | | | | biotechnology industry employed more than half |
| investors agree that the second board market will | | | | of employees, sales revenue in the U.S. |
| facilitate the establishment of more rapid | | | | biotechnology industry, 57%, R & D |
| development of the industry. State Drug | | | | investment accounted for 59% of their annual |
| Administration of various New Drugs Appropriate | | | | sales growth rate of nearly 40%. Besides the U.S., |
| extension of protection. At present, some listed | | | | the UK's Cambridge genome Park, the southern |
| companies in the biomedical field, while the risk of | | | | suburbs of Paris, France, the gene Valley, |
| investment for the industry has begun operation. | | | | Germany bio-technology demonstration areas, |
| Fourth, patent risk will be gradually released. Some | | | | biological park in Bangalore, India, gathered, |
| enterprises in China and some foreign generic | | | | including biotech companies, research, technology |
| biological products will be joined WTO, the impact | | | | transfer centers, banking, investment, services, |
| of intellectual property protection, but many | | | | etc., large number of institutions, providing a large |
| products patent is about to expire, so that these | | | | number of employment opportunities and most of |
| companies produce these products, the risk of | | | | the output. The biotechnology industry clusters in |
| gradual release. | | | | these countries and regions in the budding |
| Join the WTO, China's biomedical industry faces | | | | industrial structure, expanding the scale of the |
| the impact of the biological drugs, the import tariff | | | | industry, enhance industrial competitiveness and |
| from the point of view, the current Preparation | | | | made important contributions. |
| Drug import tariff is 20%; "WTO" after 10 years | | | | Therefore, the development of China's biomedical |
| will be reduced to 6.5% level. The impact of | | | | industry is the most critical training and |
| foreign direct access. Many biological systems in | | | | development of strong regional biomedical cluster. |